Cystoid macular edema following repeat DMEK: incidence and risk factors.

Nicole Mechleb, Costanza Baressi, Georges Caputo, Alain Saad, Youssef Abdelmassih
{"title":"Cystoid macular edema following repeat DMEK: incidence and risk factors.","authors":"Nicole Mechleb, Costanza Baressi, Georges Caputo, Alain Saad, Youssef Abdelmassih","doi":"10.1007/s00417-024-06700-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To describe the incidence of CME in re-DMEK procedures and identify the associated risk factors.</p><p><strong>Methods: </strong>Retrospective case series of 88 patients who underwent re-DMEK surgeries from January 2013 to October 2023. Surgical results were analyzed based on the cause of corneal decompensation, associated ophthalmologic factors, occurrence of CME after primary DMEK surgery, incidence of CME after re-DMEK, time interval between surgery and onset of CME, and management and outcomes of CME.</p><p><strong>Results: </strong>Primary DMEK indications were Fuchs endothelial corneal dystrophy (FECD) in 40 eyes (44.9%), PBK in 30 eyes (33.7%) and herpes simplex virus (HSV) in 10 eyes (11.2%). After the first DMEK surgery, CME occurred in 16 eyes (18%) with a mean interval of 23.4 ± 16.7 weeks. After re-DMEK surgery, CME occurred in 22.5% with a mean interval of 14.2 ± 21.9 weeks. It was a new onset in 13 eyes (65%), recurrent in 6 eyes (30%), and persistent in 1 eye (5%). On multivariate analysis, no significant association was found between the presence of ERM and CME following re-DMEK. Eyes with a history of PPV and prior CME were significantly associated with CME occurrence with odd ratios of 4.9 (95% CI: 1.04-23.1, p = 0.04) and 4.1 (95%CI: 1.2-13.5, p = 0.02) respectively.</p><p><strong>Conclusion: </strong>CME following re-DMEK occurs in 22.5% of cases, primarily within the first three months post-operatively. The main risk factors include a previous occurrence of CME after the initial DMEK and a history of PPV. However, CME does not seem to negatively impact the final visual outcomes of re-DMEK.</p>","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Graefe’s Archive for Clinical and Experimental Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00417-024-06700-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To describe the incidence of CME in re-DMEK procedures and identify the associated risk factors.

Methods: Retrospective case series of 88 patients who underwent re-DMEK surgeries from January 2013 to October 2023. Surgical results were analyzed based on the cause of corneal decompensation, associated ophthalmologic factors, occurrence of CME after primary DMEK surgery, incidence of CME after re-DMEK, time interval between surgery and onset of CME, and management and outcomes of CME.

Results: Primary DMEK indications were Fuchs endothelial corneal dystrophy (FECD) in 40 eyes (44.9%), PBK in 30 eyes (33.7%) and herpes simplex virus (HSV) in 10 eyes (11.2%). After the first DMEK surgery, CME occurred in 16 eyes (18%) with a mean interval of 23.4 ± 16.7 weeks. After re-DMEK surgery, CME occurred in 22.5% with a mean interval of 14.2 ± 21.9 weeks. It was a new onset in 13 eyes (65%), recurrent in 6 eyes (30%), and persistent in 1 eye (5%). On multivariate analysis, no significant association was found between the presence of ERM and CME following re-DMEK. Eyes with a history of PPV and prior CME were significantly associated with CME occurrence with odd ratios of 4.9 (95% CI: 1.04-23.1, p = 0.04) and 4.1 (95%CI: 1.2-13.5, p = 0.02) respectively.

Conclusion: CME following re-DMEK occurs in 22.5% of cases, primarily within the first three months post-operatively. The main risk factors include a previous occurrence of CME after the initial DMEK and a history of PPV. However, CME does not seem to negatively impact the final visual outcomes of re-DMEK.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
重复 DMEK 后的囊样黄斑水肿:发病率和风险因素。
目的:描述再DMEK手术中CME的发生率,并确定相关风险因素:方法:对2013年1月至2023年10月期间接受再DMEK手术的88例患者进行回顾性病例系列研究。根据角膜失代偿的原因、相关眼科因素、初次DMEK手术后CME的发生率、再次DMEK手术后CME的发生率、手术与CME发生之间的时间间隔以及CME的处理和结果对手术结果进行分析:结果:40 只眼睛(44.9%)、30 只眼睛(33.7%)和 10 只眼睛(11.2%)的原发性 DMEK 适应症为富克斯内皮角膜营养不良症(Fuchs endothelial corneal dystrophy,FECD)、PBK 和单纯疱疹病毒(herpes simplex virus,HSV)。首次 DMEK 手术后,16 只眼睛(18%)发生了 CME,平均间隔时间为 23.4 ± 16.7 周。再次接受 DMEK 手术后,22.5% 的患者出现 CME,平均间隔时间为 14.2 ± 21.9 周。13只眼睛(65%)为新发,6只眼睛(30%)为复发,1只眼睛(5%)为持续性。经过多变量分析,发现ERM的存在与再次DMEK后的CME之间没有明显的关联。有PPV和既往CME病史的眼睛与CME的发生显著相关,奇异比分别为4.9(95%CI:1.04-23.1,p = 0.04)和4.1(95%CI:1.2-13.5,p = 0.02):结论:22.5%的病例会在再次接受DMEK手术后发生CME,主要发生在术后头三个月内。主要的风险因素包括初次 DMEK 术后曾发生过 CME 以及有 PPV 病史。不过,CME似乎不会对再次DMEK手术的最终视觉效果产生负面影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.40
自引率
7.40%
发文量
398
审稿时长
3 months
期刊介绍: Graefe''s Archive for Clinical and Experimental Ophthalmology is a distinguished international journal that presents original clinical reports and clini-cally relevant experimental studies. Founded in 1854 by Albrecht von Graefe to serve as a source of useful clinical information and a stimulus for discussion, the journal has published articles by leading ophthalmologists and vision research scientists for more than a century. With peer review by an international Editorial Board and prompt English-language publication, Graefe''s Archive provides rapid dissemination of clinical and clinically related experimental information.
期刊最新文献
Assessment of insulin-degrading enzyme inhibitor for the treatment of corneal erosion in a rat model. Association analyses of the measurements of the photopic negative response evoked by two ISCEV protocols. Hyperreflective material evolution patterns during long term anti-VEGF therapy in neovascular age-related macular degeneration. Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases. Evaluating anterior segment stability and corneal endothelium after prolene gonioscopy assisted transluminal trabeculotomy (GATT) in open-angle glaucoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1